These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 16487616

  • 1. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.
    J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
    [Abstract] [Full Text] [Related]

  • 2. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [Abstract] [Full Text] [Related]

  • 3. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.
    Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
    [Abstract] [Full Text] [Related]

  • 4. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.
    Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, Lionetti R, Anselmo A, Toti L, Angelico M.
    J Hepatol; 2006 Apr; 44(4):702-9. PubMed ID: 16473433
    [Abstract] [Full Text] [Related]

  • 5. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK.
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [Abstract] [Full Text] [Related]

  • 6. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 7. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
    Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A.
    Liver Transpl Surg; 1999 Jul; 5(4):294-300. PubMed ID: 10388502
    [Abstract] [Full Text] [Related]

  • 8. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis.
    Samonakis DN, Mela M, Quaglia A, Triantos CK, Thalheimer U, Leandro G, Pesci A, Raimondo ML, Dhillon AP, Rolles K, Davidson BR, Patch DW, Burroughs AK.
    Transpl Infect Dis; 2006 Mar; 8(1):3-12. PubMed ID: 16623815
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study.
    Lladó L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, Torras J, Garcia-Gil A, Gonzalez-Pinto I, Castellote J, Baliellas C, Fabregat J, Rafecas A, Thosin Study Group.
    J Hepatol; 2006 Apr; 44(4):710-6. PubMed ID: 16487622
    [Abstract] [Full Text] [Related]

  • 10. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [Abstract] [Full Text] [Related]

  • 11. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, García-Herola A, Olaso V, De Juan M, Gobernado M, Mir J, Berenguer J.
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [Abstract] [Full Text] [Related]

  • 12. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation.
    Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, Furlini G, Bellusci R, Roda E, Cavallari A.
    Liver Transpl; 2002 Oct; 8(10):884-8. PubMed ID: 12360428
    [Abstract] [Full Text] [Related]

  • 13. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C.
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [Abstract] [Full Text] [Related]

  • 14. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.
    Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C, Menichetti F, Brunetto MR, Scatena F, Filipponi F.
    Transplantation; 2008 Dec 27; 86(12):1666-71. PubMed ID: 19104402
    [Abstract] [Full Text] [Related]

  • 15. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
    Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Cammà C, De Carlis L, Minola E, Quaglia A, Zavaglia C, Vangeli M, Patch D, Dhillon A, Cillo U, Guido M, Fagiuoli S, Giacomoni A, Slim OA, Airoldi A, Boninsegna S, Davidson BR, Rolles K, Pinzello G.
    Liver Transpl; 2007 May 27; 13(5):733-40. PubMed ID: 17370330
    [Abstract] [Full Text] [Related]

  • 16. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
    Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A.
    Transpl Int; 2005 Dec 27; 18(12):1336-45. PubMed ID: 16297052
    [Abstract] [Full Text] [Related]

  • 17. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, Fernández-Aguilar JL, Suárez Muñoz MA, González-Sánchez AJ, Pérez Daga JA, Ramírez Plaza CP, Carrasco Campos J, Jiménez Mazure C, Becerra Ortíz R.
    Transplant Proc; 2008 Nov 27; 40(9):2994-6. PubMed ID: 19010171
    [Abstract] [Full Text] [Related]

  • 18. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?
    Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayón M, San Juan F, Landaverde C, Mir J, Berenguer J.
    Liver Transpl; 2003 Nov 27; 9(11):1152-8. PubMed ID: 14586875
    [Abstract] [Full Text] [Related]

  • 19. Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence.
    Marubashi S, Dono K, Nagano H, Kim C, Asaoka T, Hama N, Kobayashi S, Takeda Y, Umeshita K, Monden M, Doki Y, Mori M.
    Clin Transplant; 2009 Nov 27; 23(6):904-13. PubMed ID: 19573088
    [Abstract] [Full Text] [Related]

  • 20. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
    Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, Moya A, Orbis F, Mir J, Berenguer J.
    Hepatology; 2002 Jul 27; 36(1):202-10. PubMed ID: 12085366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.